|
19 Apr |
Pear Therapeutics, Inc. today announced a deal with Sandoz, a division of Novartis, to commercialize its two lead products, reSET® and reSET-O™. In addition to an upfront payment, the deal includes research and development funding, commercial milestones, and a profit split on net sales of both therapeutics. |
|
18 Apr |
Swift Biosciences today announced the commercial release of its Accel-Amplicon Plus™ Cancer NGS Panels, a suite of nine tumor-specific and focused gene panels to facilitate targeted cancer sequencing. The Accel-Amplicon technology enables simultaneous detection of single nucleotide variants, copy number variants and small insertion and deletions to achieve comprehensive and exon-level hotspot coverage of clinically-relevant genes. |
|
16 Apr |
Boston Scientific (NYSE: BSX) today announced that it has acquired nVision Medical Corporation, a privately-held company focused on women’s health. nVision developed the first and only device cleared by the U.S. Food and Drug Administration to collect cells from the fallopian tubes, offering a potential platform for earlier diagnosis of ovarian cancer. Recent studies have confirmed that several major types of ovarian cancer appear to originate from the fallopian tubes. A 32-Year-Old’s Startup, Inspired By A Health Scare, Sells For $275 Million |
|
29 Mar |
The International Society for CNS Drug Development (ISCDD) announced today that Corey McCann, M.D., Ph.D., President and CEO of Pear Therapeutics, Inc., is the recipient of the ISCDD 2018 Innovation Award at its 16th Annual Meeting. |
|
22 Mar |
BioIQ, a healthcare technology company driving the shift to value-based care, announced today it has raised $26.5M. The financing was led by HealthQuest Capital, with Arboretum Ventures and select insiders joining the syndicate. BioIQ will use the funding to fuel continued growth and support its mission to help transform the U.S. healthcare system and impact more than 100 million lives. |
|
21 Mar |
Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH). Twin Cities med-tech company NxThera to be sold to Boston Scientific in $400M dealTwin Cities med-tech company NxThera Inc. has agreed to be sold to Boston Scientific Corp. in a deal worth up to about $400 million, the companies announced Wednesday. |
|
19 Mar |
A new category of prescription medical treatments, what executives call digital therapeutics, comes in the form of mobile apps. Health tech companies are making a big push to digitize medicine, introducing novel tools like digital pills that track when patients take their drugs and smart spoons that can automatically adjust to hand tremors. |
|
16 Mar |
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) platform technology to treat endourological conditions, announced study findings that demonstrate its Rezūm® System provides effective and durable improvements in benign prostatic hyperplasia (BPH) symptom scores with clinical progression rates five times lower when compared to daily, long-term use of pharmaceutical agents three years after treatment. |
|
13 Mar |
Strata Oncology, a precision oncology company, today announced that Aurora Health Care, the largest healthcare system in Wisconsin, and University of Texas Health Sciences at Houston (UTHealth) have joined the Strata Precision Oncology NetworkTM (Network). |
|
21 Feb |
NxThera, Inc., a medical device company pioneering the application of its Convective Water Vapor Energy (WAVE®) technology to treat endourological conditions, today announced the launch of the Rezūm® Center of Excellence program recognizing top urologists across the country for their expertise in treating benign prostatic hyperplasia (BPH), or enlarged prostate. |
